13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Vertu

    Acronym: 

    Vertu

    ACTRN/NCT /ethics: 

    ACTRN12615000407594

    Scientific title: 

    A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in patients with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT) Glioblastoma (brain cancer) (VERTU study)

    Summary of trial and patient characteristics

    Cancer Type Brain & central nervous system
    Trial Type Treatment
    Phase Phase II Tumour Stream Brain Cancer
    Age Range 18 years and older Cancer Stage In Situ
    Sex Both Anticipated Start Date 2015-12-01
    Molecular Target Anticipated End Date
    Cancer Type Brain & central nervous system
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Brain Cancer
    Cancer Stage In Situ
    Anticipated Start Date 2015-12-01
    Anticipated End Date

    Trial Summary

    This study aims to evaluate the safety and effectiveness of a combination of veliparib with radiotherapy, followed by a combination of veliparib with temozolomide (a chemotherapy), to treat patients with newly diagnosed glioblastoma multiforme (a type of brain tumour).

    Lay Summary

    A Randomised Phase II study of Veliparib, Radiotherapy and Temozolomide in patients with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT) Glioblastoma (brain cancer) (VERTU study)

    Sponsor / Cooperative group

    The University of Sydney

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Recruitment on Hold